M&T Bank
RVNC

M&T Bank’s Revance Therapeutics, Inc. RVNC Stock Holding History

M&T Bank’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,818
Closed -$357K – 1629
2021
Q3 		$357K Hold
12,818
– – ﹤0.01% 1158
2021
Q2 		$379K Hold
12,818
– – ﹤0.01% 1158
2021
Q1 		$358K Buy
12,818
+1,512
+13% +$41.8K ﹤0.01% 1155
2020
Q4 		$320K Hold
11,306
– – ﹤0.01% 1304
2020
Q3 		$284K Hold
11,306
– – ﹤0.01% 1260
2020
Q2 		$276K Buy
11,306
+49
+0.4% +$967 ﹤0.01% 1231
2020
Q1 		$167K Sell
11,257
-2,537
-18% -$52.5K ﹤0.01% 1362
2019
Q4 		$224K Hold
13,794
– – ﹤0.01% 1218
2019
Q3 		$179K Buy
13,794
+1,960
+17% +$24K ﹤0.01% 1451
2019
Q2 		$153K Buy
+11,834
New +$149K ﹤0.01% 1457

Other funds holding RVNC

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

M&T Bank's RVNC Position: Q4 2021 in Review

M&T Bank sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2021, closing a stake of 12,818 shares — an estimated $357K sold.

M&T Bank first reported a position in RVNC in Q2 2019 and held it in 10 quarters. The position peaked at $379K in Q2 2021. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2021.

  • M&T Bank reported no remaining Revance Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • M&T Bank sold 12,818 Revance Therapeutics, Inc. shares in Q4 2021, an estimated $357K.
  • M&T Bank first reported a position in Revance Therapeutics, Inc. in Q2 2019 and held it in 10 quarters.
  • M&T Bank's Revance Therapeutics, Inc. position peaked at $379K in Q2 2021.
  • 151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2021.

Based on M&T Bank's 13F filing for Q4 2021, filed 7 Feb 2022.